Recalled Heartburn Pill Zantac Sets Fire To Glaxo and Sanofi Shares As Billions In Market Value Goes Up In Smoke
Sanofi SA (NASDAQ: SNY), GSK Plc (NYSE: GSK), and Haleon Plc (NYSE: HLN) have lost a combined $40 billion in mar
Passage Bio Commences Initial-Stage Brain Disorder Study
Passage Bio (NASDAQ: PASG) has dosed the first patient in the global Phase 1/2 upliFT-D clinical trial evaluating PBFT02 for the treatment of patients with frontotemporal dementia (FTD) with granulin (GRN) mutations.
Deciphera’s Cancer Drug Tops Pfizer’s Sutent On Safety Front In Gastrointestinal Cancer
The Journal of Clinical Oncology has published results from Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) INTRIGUE Phase 3 study of Qinlock (ripretinib) for advanced…
aTyr Pharma Shares Ascend As FDA Grants Fast Track Status To Lung Disease Candidate
The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to aTyr Pharma’s (NASDAQ: LIFE) lead therapeutic candidate, efzofitimod (ATYR1923), for the treatment of pulmonary sarcoidosis, a major form of interstitial lung disease.
Cardinal Health Names New Chief Executive, Posts Mixed Q4 Earnings
Cardinal Health Inc (NYSE:CAH) has reported Q4 FY22 adjusted EPS of $1.05, up 36% Y/Y, missing the consensus of $1.17.…
Recap Of Wednesday’s Biotech Catalysts – End Of the Day Summary
Bristol Myers Squibb (NYSE:BMY) and 2seventy bio (NASDAQ:TSVT) announced positive topline results from KarMMa-3, a Phase 3 study…
Molina Healthcare Receives Notice Of Intent To Award Mississippi Medicaid Contract
Molina Healthcare, Inc. (NYSE:MOH) ("Molina") announced that its Mississippi health plan subsidiary has been notified by the Mississippi Division of Medicaid (DOM) of its intent to award a Medicaid Coordinated
This Analyst Says Zentalis’ Increased Focus On WEE1 Program Is ‘Prudent’, Slashes Price Target By 37%
Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) decided to discontinue the development of oral SERD asset ZN-c5 and EGFR inhibitor ZN-e4 following the completion…
ReShape Lifesciences’ GIBI HD Calibration Tubes Scores FDA Approval For Tummy Tuck Procedures
ReShape Lifesciences Inc (NASDAQ:RSLS) has received FDA 510(k) clearance for the disposable Gastro Intestinal Balloon Indicator (GIBI HD) calibration tube for…
ReShape Lifesciences Shares Soar As FDA Announced Clearance To GIBI HD Calibration Tubes In Weight Loss Procedures
The U.S. Food and Drug Administration (FDA) has announced 510(k) clearance to ReShape Lifesciences’ (NASDAQ: RSLS) Gastro Intestinal Balloon Indicator (GIBI HD) calibration tube for use in gastric and bariatric surgical procedures.